Tiny microbes make a huge difference in our health. These internal ecological systems utilize communication or signaling to maintain this health, effecting immune system function. This podcast shares an important discovery in this communication that influences receptivity to cancer treatment.
Listen and learn
Dr. Kathy McCoy is a professor in the Department of Physiology and Pharmacology at the University of Calgary and the director of the International Microbiome Centre. Her research is focused on interactions between the microbiome and immune system and she shares an exciting just-published study that presents a key finding in cancer treatment.
Specifically, her research asked how gut microbes play a rule in influencing or regulating the efficacy of immune checkpoint blockade therapy or cancer immunotherapy. She says that scientists have known for a few years that our microbiome is associated with immunotherapy success or lack thereof, but needed more information to make a difference in treatment.
Here’s the big idea behind her findings: while researchers have known there’s a microbial immune conversation, they now know that it’s a three-way conversation rather than a two-way conversation. In addition to the microbes and immune system players, metabolites sent out by microbes have a say; furthermore, this conversation gets enhanced by cancer immunotherapy.
More specifically, they found that one of these metabolites, inosine, binds to a receptor present on T-cells and causes a signal transduction cascade that makes that T-cell turn on an anti-tumor response—it makes the cytokines necessary to attack cancer cells. If a patient doesn’t have this metabolite, the immunotherapy may not work as well. The hope is researchers can figure out how to encourage this metabolite in patients. Listen in for more details about this study and about its life-changing implications.
For more, see her lab website: kathymccoylab.ca.
Available on Apple Podcasts: apple.co/2Os0myK